Lung Cancer Advisory Board

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/raphael_bueno-1.jpg

Raphael Bueno, M.D.

Bueno is Associate Chief of Thoracic Surgery at Brigham and Women’s Hospital and Associate Professor of Surgery at Harvard Medical School. Dr. Bueno is a busy clinical surgeon with expertise in the surgical management of complex lung cancer. Dr. Bueno is also a funded investigator who has been working in the field of prognosis and diagnosis of thoracic malignancies. He has a particular interest in developing diagnostic and prognostic tests for patients with lung cancer. He has been a member of the Cancer and Leukemia Group B, a cooperative group for clinical and translational cancer research, for the past decade and has participated in several multicenter research efforts through this and other organizations.

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/nicholas_campbell.jpg

Nicholas Campbell, M.D.

Dr. Nicholas Campbell earned his medical degree at the Medical College of Georgia. He then completed his residency in internal medicine, followed by a fellowship in medical oncology, both at The University of Chicago, where he served as Chief Fellow. Dr. Campbell is now a clinical assistant professor at NorthShore University HealthSystem, a teaching affiliate hospital of The University of Chicago. Dr. Campbell’s clinical research interests include novel therapeutics, trial development, and database management in thoracic oncology.

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/phillip_dennis.jpg

Phillip Dennis, M.D., Ph.D.

Dr. Phillip Dennis attended the University of Virginia as an Echols Scholar and obtained his Ph.D. and M.D. degrees from New York University as part of the Medical Scientist Training Program. Dr. Dennis completed training in internal medicine and medical oncology at Johns Hopkins University and joined the National Cancer Institute (NCI) as a tenure track investigator in 1999. Since then, Dr. Dennis’s scientific and clinical interests have focused on studying signal transduction pathways that contribute to formation, maintenance, and therapeutic resistance of lung cancer. Dr. Dennis became a senior investigator in the Medical Oncology Branch in 2006. Dr. Dennis currently heads the Signal Transduction Section in the Medical Oncology Branch. Dr. Dennis is a recipient of the Alton Ochsner Award Relating Smoking and Health and a National Institutes of Health (NIH) Merit Award and was elected to the American Society for Clinical Investigation in 2007.

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/gregory_otterson1.jpg

Gregory Otterson, M.D.

Dr. Otterson is Professor in the College of Medicine at Ohio State University (OSU) Comprehensive Cancer Center James Cancer Hospital. Dr. Otterson is broadly interested in improving the care and understanding of thoracic malignancies (adenocarcinoma, squamous carcinoma, large cell carcinoma, never-smoking adenocarcinoma, small cell lung cancer, mesothelioma, and thymic cancers). His research centers around the genetic and epigenetic changes in lung cancers, particularly microRNAs. Therapeutically, he is interested in understanding how better to target specific therapies to specific patients, that is, understanding which patients will respond to which therapeutic maneuvers. Dr. Otterson has active collaborations within OSU, including in the Division of Cancer Genetics (Carlo Croce), the School of Public Health (Mary Ellen Wewers and Amy Ferketich), and the Division of Pulmonary and Critical Care Medicine (Patrick Nana-Sinkam). Outside of OSU, he works with investigators at the University of Minnesota and also actively works with the Cancer and Leukemia Group B, having been National Principal Investigator on three studies through the Respiratory Committee.

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/ravi_salgia.jpg

Ravi Salgia, M.D., Ph.D.

Dr. Ravi Salgia is tenured Professor of Medicine, Pathology and Dermatology, and Director of the Thoracic Oncology Program and Aerodigestive Tract Program Translational Research Lab in the Section of Hematology/Oncology at The University of Chicago Medical Center in Illinois. Dr Salgia is also an attending physician in the Department of Medicine, Section of Hematology/Oncology, University of Chicago. Dr Salgia is a member of the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer, among others. He is also a member of the Committee on Cancer Biology and Clinical Trials Review Committee at The University of Chicago. Dr Salgia’s research interests focus on novel therapeutics against lung cancer. He has been an invited lecturer to more than 300 symposia and seminars. Dr Salgia has been honored with numerous awards, including recently being named one of the Top Doctors in America. Dr Salgia is a member of the editorial board for the Journal of Carcinogenesis, Update on Cancer Therapeutics, and Current Women’s Health Reviews. He also serves as associate editor for the Journal of Environmental Pathology, Toxicology, and Oncology. He has authored or coauthored more than 100 peer-reviewed publications, 125 abstracts, and 30 book chapters. Dr Salgia earned a medical degree from Loyola University School of Medicine in Chicago, Illinois, where he also obtained a doctorate of philosophy. He did his internship/residency in internal medicine at The Johns Hopkins Hospital. He also did his medical oncology fellowship at Dana-Farber Cancer Institute (DFCI) and Harvard Medical School, Boston, Massachusetts. He was on faculty at DFCI for a decade before moving to The University of Chicago.

 

https://www.cancercommons.org/wordpress/wp-content/uploads/2017/01/george_simon.jpg

George Simon, M.D.

Dr. Simon is currently Associate Professor of Medicine and Oncology at the Medical University of South Carolina, Charleston. He also serves as Assistant Director of Clinical Investigation at the Hollings Cancer Center and is the Burtschy Family Distinguished Endowed Chair in Cancer Research. Previously, he served as the director of the Thoracic Oncology Program, Department of Medical Oncology at Fox Chase Cancer Center in Philadelphia, Pennsylvania. After earning his medical degree from the Christian Medical College and Hospital, Ludhiana in Punjab, India, Dr. Simon completed residencies in internal medicine at the Christina Medical College and Hospital, Punjab, India and St. Joseph’s Hospital, Denver, Colorado, and a fellowship in medical oncology and hematology at the University of Colorado Health Sciences Center in Denver. Previously, Dr. Simon has served as the director of a mesothelioma research program at the H. Lee Moffitt Cancer Center, Tampa, Florida. Prior to joining the H. Lee Moffitt Cancer Center, Dr. Simon served as Director of Clinical Investigation in the Division of Hemotology and Oncology at the Denver Health Medical Center. Dr. Simon has served as a member of the National Comprehensive Cancer Network (NCCN) Non-Small Cell Lung Cancer Guidelines panel, American College of Chest Physician Lung Cancer Guidelines committee, and in the Thoracic Core committee of the South West Oncology Group. He currently serves in the Thoracic Core committee of the Eastern Cooperative Oncology Group. Dr. Simon is an ad hoc reviewer for several panels of the National Institutes of Health, National Cancer Institute, and Department of Defense, and also a reviewer for several journals including Cancer Research, Clinical Cancer Research, Chest, Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology, and Indian Journal of Cancer. He is author or coauthor of more than 70 peer-reviewed research publications, 13 book chapters, and more than 65 abstracts.